0
Intellia Therapeutics, Inc. Banner Image

Intellia Therapeutics, Inc.

  • Ticker NTLA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Intellia Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietaryMore programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Intellia Therapeutics, Inc.

Most Recent Annual Report

Intellia Therapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Intellia Therapeutics, Inc. does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports